Abstract
Objectives Diffuse gliomas, due to their infiltrative properties, still lack effective treatment options. Recent research indicates that infiltration, malignancy, and symptoms such as epilepsy are related to synaptic connections between infiltrating glioma cells and cytotoxic levels of glutamate release. We previously showed that high-resolution 7T magnetic resonance spectroscopic imaging (MRSI) can resolve metabolic heterogeneities in gliomas. With this study, we evaluated 7T MRSI-derived glutamate (Gln) and glutamine (Glu) ratio maps for their use in defining infiltrative tumor activity in the peritumoral region.
Materials and Methods We analyzed 7T MRSI scans of 36 patients with low- and high-grade gliomas. Within the visible tumor and a peritumoral shell, we calculated medians and Dice similarity coefficients (DSC) for nine metabolic ratios with and without hotspot thresholding and evaluated their correlation to and statistical significance between clinical parameters (e.g., tumor-associated epilepsy, IDH status, grade).
Results The Glu/tCr (total creatine) median was significantly higher in the peritumoral VOI (1.13) compared to the tumor (0.92) and normal-appearing white matter (NAWM, 0.87), while the Gln/tCr median was highest in the tumor (0.77, vs 0.44 peritumoral and 0.33 in NAWM, all significantly different). Glu/tCho (total choline) was significantly higher in the peritumor as well (3.44 vs 2.23 tumoral and 2.06 in NAWM). Peritumoral DSCs for Glu/tCr and Gln/tCr hotspots were comparable (0.53 to 0.51). Peritumoral Gln/Glu was significantly different between patients with and without tumor-associated epilepsy, and intratumoral (Glu+Gln)/tCr was significantly different between IDH mutation and wildtype. IDH mutation correlated negatively with the intratumoral (Glu+Gln)/tCr median (-0.53) and high grade correlated with intratumoral Glx/tNAA, Glx/tCr, and Gln/tCr medians (0.50/0.53/0.58).
Conclusions 7T MRSI can not only map relevant metabolic information in the structurally visible tumor volume, but also detect infiltration in the peritumoral area. Gln and Glu are candidates for the development of presurgical imaging and treatment monitoring.
Competing Interest Statement
Julia Furtner has received honoraria for lectures and consultation from the following for-profit companies: Novartis; Seagen; Sanova; and Servier. Matthias Preusser has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer; Bristol-Myers Squibb; Novartis; Gerson Lehrman Group (GLG); CMC Contrast; GlaxoSmithKline; Mundipharma; Roche; BMJ Journals; MedMedia; Astra Zeneca; AbbVie; Lilly; Medahead; Daiichi Sankyo; Sanofi; Merck Sharp & Dohme; Tocagen; Adastra; Gan & Lee Pharmaceuticals; Servier; Miltenyi; Boehringer-Ingelheim; Telix; Medscape; and OncLive.
Funding Statement
This research was funded in whole, or in part, by the Austrian Science Fund (FWF) grants 10.55776/KLI646 and 10.55776/KLI1089. For open access purposes, the author has applied a CC BY public copyright license to any author-accepted manuscript version arising from this submission. Further funding was received from the City of Vienna Fund for Innovative Interdisciplinary Cancer Research project 23088. The financial support by the Austrian Federal Ministry for Digital and Economic Affairs and the National Foundation for Research, Technology and Development, and the Christian Doppler Research Association, is gratefully acknowledged.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the Medical University of Vienna gave ethical approval for this work (study number 1991/2018).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Image data produced in the present study are available upon reasonable request to the authors after institutional data clearing house approval. Derived numerical values are included in the supplementary data.
